RE: Chemical Hair Relaxers and Hormone-Sensitive Cancers — Plaintiff Science, Endocrine-Disruption Mechanism, and the April 2026 Daubert Posture
MDL Reference: In re: Hair Relaxer Marketing, Sales Practices, and Products Liability Litigation, MDL No. 3060 (N.D. Ill., Hon. Mary M. Rowland).
Date: May 2026
Classification: Background research brief — not legal advice. Citations to primary peer-reviewed sources have been verified to publicly accessible URLs as of the memo date. Secondary-source claims and snapshot values (case counts, regulatory deadlines) are flagged inline and detailed in §9.5; recipients should clear the §9.5 backlog before relying on those elements in motion practice or expert testimony.
The chemical hair relaxer MDL has matured into a Daubert-ready litigation built on a distinctive evidentiary architecture. Unlike pharmaceutical mass torts where one chemical drives one endpoint, the relaxer record links a mixture of endocrine-disrupting compounds — formaldehyde and formaldehyde-releasing agents, phthalates, parabens, cyclosiloxanes — to multiple hormone-sensitive endpoints (uterine, ovarian, and breast cancer; uterine fibroids). The case is structurally heavier than a single-chemical, single-disease theory, but its Bradford Hill profile is unusually complete.
Five published epidemiological studies between 2012 and 2023, all from prospective cohort designs, return elevated risk estimates in the same direction. Chang et al. (2022) — the Sister Study — reports HR 1.80 (95% CI 1.12–2.88) for ever-use of straighteners in the prior 12 months and HR 2.55 (95% CI 1.46–4.45) at frequent use, with absolute lifetime-incidence rising from 1.64% (never-users) to 4.05% (frequent users). White et al. (2021) reports HR 2.45 for ovarian cancer at frequent use, rising to 4.25 for non-serous ovarian cancer. Bertrand et al. (2023) — the Black Women's Health Study — finds a dose-dependent uterine-cancer signal in postmenopausal women with long-duration use (HR 1.71 at ≥20 years). Eberle et al. (2020) reports a statistically significant dose-response trend for breast cancer (p for trend = 0.02), with frequent users showing approximately 31% higher risk. Wise et al. (2012) establishes uterine fibroids as a hormonally mediated downstream condition (IRR 1.17 with positive trends for frequency, duration, and chemical-burn count).
Three structural facts now drive the case:
The April 1, 2026 Rule 702/Daubert motions on general causation are the pivotal gate. As of February 2026 the docket sits at approximately 11,195 pending cases — fifth-largest active MDL in the federal system (MDL Update, February 2026 — verify against the JPML pending-MDL-dockets report). Judge Rowland has expanded the bellwether discovery pool from 16 to 40 cases, targeting up to 12 for trial. First bellwether trials are expected mid-2027.
The strongest plaintiff openings are (i) Chang et al. 2022 (top-tier journal, prospective design, dose-response intact), (ii) the McDonald 2021/2022 in-vitro receptor-activity work that preempts the "which chemical?" defense at the mixture-framing level, (iii) the OSHA salon-measurement data, (iv) the FDA's own 2023 acknowledgment, and (v) the racial-disparity / environmental-justice frame supported by the EWG 2016/2025 product-hazard analyses. The largest plaintiff exposures are (a) the BWHS premenopausal null result, (b) the mixture problem (no single chemical isolated as the causal agent), (c) Sister Study selection-bias arguments, and (d) the regulatory-compliance defense, narrowed but not eliminated by the unfinalized 2023 proposed ban.
Chemical hair relaxers permanently straighten textured hair by breaking and reforming the disulfide bonds of the hair shaft. Two formulation families dominate: lye-based (sodium hydroxide, NaOH) and no-lye (calcium hydroxide plus guanidine carbonate; lithium or potassium hydroxide variants). Both raise scalp pH to approximately 12–13, producing thermal and chemical injury to the scalp epithelium. EWG's 2025 review of 4,011 products marketed to Black women found that 78% of evaluated relaxers contained sodium hydroxide, calcium hydroxide, or both (EWG, February 2025; Skin Deep methodology — see §9.5).
Beyond the active alkali, the formulations carry an extensive and largely undisclosed chemical inventory. Helm et al. (2018, Environmental Research) is a product-composition study using GC/MS analytical chemistry, not an epidemiologic outcome study — it documents the chemical exposure population, supporting the mixture-causation framing rather than the exposure-outcome association. Helm tested 18 hair products and identified 45 endocrine-disrupting or asthma-associated chemicals. Diethyl phthalate (DEP) was found in 72% of products. 84% of detected chemicals were not listed on the product label. Hair-relaxer products contained DEHP at concentrations up to 90 µg/g. Children's relaxer products contained five chemicals regulated by California's Proposition 65 or prohibited under EU cosmetics regulation. The plaintiff theory therefore identifies a chemical population — not a single compound — and argues that the mixture, as commercially formulated, is hormonally active.
The chemical population of concern includes formaldehyde and formaldehyde-releasing agents (methylene glycol, DMDM hydantoin, quaternium-15); phthalates (DEP, DEHP, dibutyl phthalate); parabens (methylparaben, propylparaben); cyclosiloxanes (D4, D5); and the active alkalis themselves, which produce the chemical-burn pathway documented in Wise et al. (2012).
Two routes of exposure operate simultaneously during application. Dermal absorption occurs through scalp skin chemically compromised by alkali-driven barrier disruption; the scalp is highly vascularized and contact times of 15–30 minutes are typical. Inhalation of volatilized formaldehyde accelerates during heat-activated steps; OSHA salon measurements document airborne formaldehyde concentrations during the final blow-dry phase as high as 10 ppm — five times the OSHA STEL (§4 below). Biomarker studies confirm the absorption pathway is operational in real consumer use: hair-product use is associated with elevated urinary concentrations of phthalate metabolites, phenols, and parabens (NIEHS, 2020).
The litigation cohort is overwhelmingly female and disproportionately Black. Approximately 66% of Black women report using chemical hair relaxers (NBC News, citing published research, 2023; primary citation pending — see §10 and §9.5; do not deploy at deposition until cleared). Black women initiate use at earlier ages — frequently in childhood — and persist for longer durations (NIH News Release, October 2022). The exposure window for the plaintiff cohort therefore extends across decades and includes critical developmental windows of hormonal sensitivity. The "long exposure tail" — women with 20+ years of use — is the population in which Bertrand et al. (2023) detected the strongest BWHS signal.
The general-causation case rests on five published prospective cohort studies supported by direct mechanistic evidence (McDonald 2021/2022; Helm 2018; Lu et al. 2010 on formaldehyde DNA adducts).
Chang et al. (October 2022), JNCI — Sister Study uterine cancer. Prospective cohort of 33,947 U.S. women aged 35–74 with intact uterus, enrolled 2003–2009, followed for ~11 years. 378 incident uterine cancers. Ever vs. never use of straightening products in the previous 12 months: HR 1.80 (95% CI 1.12–2.88). Frequent use (>4 times/year): HR 2.55 (95% CI 1.46–4.45) — more than double the never-user risk. The absolute-risk shift — 1.64% of never-users would develop uterine cancer by age 70 versus 4.05% of frequent users — is a 2.5-fold absolute-risk gradient (Chang et al., DOI 10.1093/jnci/djac165). The association was specific to straightening products; permanent dyes and body waves did not show the same signal in the same cohort. Product-class specificity supports the causal-inference analysis as a coherence finding (see §6.6).
Bertrand et al. (2023), Environmental Research — BWHS uterine cancer. Prospective cohort of 44,798 Black women with intact uterus, followed 1997–2019. 347 incident uterine cancers. Overall heavy use (≥15 years, ≥5 times/year) vs. never/light use: HR 1.18 (95% CI 0.81–1.71) — not statistically significant in the full cohort. Stratified by menopausal status: postmenopausal moderate use HR 1.60 (95% CI 1.01–2.53); heavy use HR 1.64 (95% CI 1.01–2.64); ≥20 years use HR 1.71 (95% CI 1.08–2.72). Premenopausal results null. The postmenopausal effect modification is biologically plausible: postmenopausal women have lower endogenous estrogen, so an exogenous estrogenic exposure is proportionally larger and the carcinogenic relevance higher.
White et al. (2021), Carcinogenesis — Sister Study ovarian cancer. Prospective cohort of 40,559 Sister Study participants. Frequent use (>4 times/year): HR 2.45 (95% CI 1.27–4.73). Non-serous ovarian cancer subtype HR 4.25 (95% CI 1.07–16.9); serous not statistically significant (HR 1.38, 95% CI 0.47–4.04). The 2.45 point estimate is the largest in the relaxer literature. Wide confidence intervals reflect smaller case counts but the histologic specificity (non-serous, not serous) is mechanistically interpretable: high-grade serous ovarian carcinomas are characterized by near-universal TP53 mutation and frequently carry BRCA1/2 mutations driving homologous-recombination deficiency. Non-serous tumors — endometrioid and clear-cell histologies — are more closely tied to estrogen signaling, including hormone-receptor expression and association with endometriosis. The histologic specificity of the White finding is mechanistically interpretable on the estrogen-signaling axis.
Eberle et al. (2020), International Journal of Cancer — Sister Study breast cancer. Prospective cohort of 46,709 Sister Study women. Chemical-straightener ever-use: HR 1.18 (95% CI 0.99–1.41). Frequent users (per Eberle's frequency stratification — confirm exact categories from Table 2 before deployment) showed approximately 31% higher breast-cancer risk; the dose-response trend across frequency categories was statistically significant (p for trend = 0.02). Permanent hair-dye use stratified by race showed 45% higher breast-cancer risk in Black women (HR 1.45, 95% CI 1.10–1.90) versus 7% in white women (HR 1.07, 95% CI 0.99–1.16) — a racial-disparity stratification supporting the differential-vulnerability theory.
Wise et al. (2012), American Journal of Epidemiology — BWHS uterine fibroids. 23,580 premenopausal Black women followed 1997–2009. Ever vs. never use: incidence rate ratio 1.17 (95% CI 1.06–1.30). Positive dose-response trends for frequency, duration, and number of self-reported chemical burns. Fibroids are estrogen-dependent benign tumors; the Wise finding establishes that relaxers affect hormonally mediated uterine conditions broadly. The chemical-burn dose-response is mechanistically important — it links visible scalp injury (a marker of barrier disruption) to systemic outcome.
The plaintiff-favorable feature of this literature is convergence across three independent design choices: prospective cohort enrollment (eliminating recall bias); demographically distinct cohorts (Sister Study U.S.-population; BWHS exclusively Black women); and multiple endpoints. No published primary epidemiological study reports a null or protective effect for chemical straightener use against this constellation of endpoints. A 2024 systematic review in European Journal of Obstetrics & Gynecology and Reproductive Biology (full-text confirmation on the §9.5 backlog) is reported to confirm consistent associations across multiple study designs. (A 2025 NIH-affiliated publication on hair-relaxer use and non-reproductive cancer endpoints would expand the scope of the science if confirmed; pending §9.5 confirmation, this material is not load-bearing for the April 2026 Daubert posture.)
The litigation gap defense will exercise is the absence of a controlled experimental design — there is no RCT of relaxer use versus a non-exposure arm followed for cancer endpoints. There will not be one; ethics review boards will not approve randomization to a regimen with documented carcinogen exposure. Plaintiffs' answer is a structural Bradford Hill argument anchored on convergent observational design and direct mechanistic evidence; multiple post-Daubert mass-tort rulings on hormonally mediated cancer endpoints have accepted analogous architecture (cite operative MDL Daubert orders applicable to the briefing here).
The strongest mechanistic evidence is McDonald et al. (2021/2022, Journal of Exposure Science & Environmental Epidemiology). McDonald used reporter-gene assays in vitro incorporating natural steroid receptors to evaluate six commonly used Black hair-care products — each used by more than 10% of the population in the Greater New York Hair Products Study. The findings: all six products displayed hormonal activity across multiple receptor pathways; three were estrogen agonists at 12.5–20 ng/g EEQ; five were androgen antagonists at 20–25 ng/g AEQ; four showed both agonist and antagonist activity toward progesterone and glucocorticoid receptors.
The mechanistic significance is that the products as commercially formulated — applied as extracts to receptor-expressing cell systems — bind and modulate steroid-hormone receptors. McDonald defeats the defense argument that plaintiffs cannot identify "the chemical" responsible at the level of conceptual framing: the exposure, as analyzed, is the product-extract, not a single chemical. McDonald does not by itself establish in-vivo carcinogenesis; the chain from receptor activation to cancer endpoint is supplied by the parallel epidemiological associations (Chang, White, Bertrand, Eberle, Wise) and the IARC Group 1 mechanistic record for the formaldehyde component.
Formaldehyde (Group 1 carcinogen, IARC Monograph 100F) is formally attributed by IARC to nasopharyngeal cancer and leukemia. IARC Group 1 establishes the carcinogenic mechanism; the specific cancers IARC formally attributes differ from the relaxer-litigation endpoints, but the genotoxic mechanisms documented are mechanism-portable to systemic exposure: DNA adduct formation (Lu et al., Toxicological Sciences, 2010, demonstrated N2-hydroxymethyl-deoxyguanosine adducts); DNA-protein crosslinks blocking replication and repair; DNA-DNA interstrand crosslinks producing genomic instability; reactive oxygen species generating oxidative damage; and chromosome aberrations documented in formaldehyde-exposed workers' peripheral lymphocytes and nasal mucosa (NTP 15th Report on Carcinogens). Each pathway is documented in primary literature; collectively they describe a mechanistic chain from exposure to mutation to cancer that does not depend on hormone-receptor binding. Plaintiffs operate on two parallel mechanistic theories — the formaldehyde genotoxic pathway and the broader endocrine-disruption pathway — which means defense attacks on one do not foreclose the other.
Phthalates in hair relaxers act through multiple endocrine pathways. DEHP and dibutyl phthalate bind to androgen and estrogen receptors but block normal hormone response, functioning as anti-androgenic and weakly anti-estrogenic agents (Frontiers in Environmental Science, 2015). At low doses, phthalate mixtures exhibit additive estrogenic activity. The anti-androgenic mechanism shifts the estrogen-androgen ratio in tissue, increasing relative estrogenic stimulation in estrogen-sensitive tissues such as endometrium.
Defense will press the "mixture problem" — that hair relaxers contain dozens of compounds, no single chemical has been isolated, and dose-response analysis on a multi-component exposure is hopelessly confounded. McDonald 2021 answers the conceptual core of this argument at the framing level. McDonald did not test individual chemicals in isolation; McDonald tested the products as commercially formulated. The products are hormonally active in vitro. The mixture is the exposure; the mixture is hormonally active at the receptor level; the mixture is what plaintiffs were exposed to. The chemical-by-chemical disaggregation defense seeks is not the question that the epidemiology answers and is not what Daubert "fit" requires.
The formaldehyde exposure data is the single hardest factual element for defense to attack at Daubert. Unlike epidemiological associations, the OSHA salon air-monitoring data is a measurement.
OSHA permissible exposure limits under 29 CFR 1910.1048: PEL 0.75 ppm (8-hour TWA); STEL 2 ppm (15-minute); action level 0.5 ppm (8-hour TWA, triggering monitoring and medical surveillance); irritation threshold 0.1 ppm. These are derived from worker-protection studies and apply to occupational settings presumed to use PPE and engineering controls.
Measured levels in salons. OSHA conducted air sampling during hair-smoothing/straightening treatments in multiple salons. The published findings (https://www.osha.gov/hair-salons):
| Salon | Phase | Measured Level | Multiple of STEL |
|---|---|---|---|
| Salon A | Application/blow dry | 4 ppm | 2× STEL |
| Salon B | Application/blow dry | 2.5 ppm | 1.25× STEL |
| Salon C | Application/blow dry | 5.5 ppm | 2.75× STEL |
| Salon C | Final blow dry | 10 ppm | 5× STEL |
The 15-minute time-weighted averaging method was applied to phases extending beyond 15 minutes. Multiple independent studies confirmed formaldehyde concentrations in salon air during application running 2 to 3 times OSHA limits. The 10 ppm Salon C measurement is particularly load-bearing — OSHA documented an actual stylist exposure at 10.12 ppm, more than five times the legal STEL in a real, occupied work environment. (Source-verification priority: confirm the exact OSHA enforcement record from which the figure derives; on re-verification backlog.)
Home-use considerations. Home application generally lacks the engineering controls available in professional salons. Consumer use occurs in bathrooms with limited ventilation, often at higher contact times than label directions specify. The exposure profile in home use is therefore plausibly worse than in salons. The plaintiff cohort includes both salon clients and home users.
"Formaldehyde-free" labels. Many products marketed as "formaldehyde-free" contain methylene glycol or other formaldehyde-releasing agents that liberate formaldehyde gas when heated. The FDA has identified this labeling as misleading and uses the operational terminology "hair smoothing products that release formaldehyde when heated" (https://www.fda.gov/cosmetics/cosmetic-products/hair-smoothing-products-release-formaldehyde-when-heated). The mismatch between consumer-facing labeling and chemical reality is operative in the failure-to-warn theory.
The relaxer litigation has a dimension that PFAS, hernia mesh, and Depo-Provera lack: a clear, documentable racial-disparity profile in both exposure and outcome. The disparity is part of the substantive Daubert case (it bears on biological plausibility through differential vulnerability and on dose-response through differential exposure intensity) and part of the trial-presentation case (it carries jury-relevant moral weight).
Usage patterns and exposure burden. Approximately 66% of Black women report using chemical hair relaxers, compared with much smaller shares of white and Hispanic women (NBC News, citing published research, 2023; primary citation pending — see §9.5). Black women initiate use at earlier ages — frequently in childhood — than other racial and ethnic groups (NIH News Release, October 2022). Products marketed to Black women are used more frequently and for longer durations.
Product-safety disparities. The Environmental Working Group's two analyses of products marketed to Black women provide the population-level safety contrast. The 2016 baseline found fewer than one-quarter of products marketed to Black women rated as low hazard. The 2025 update of 4,011 products found only 21% rated as low hazard in EWG's Skin Deep database; approximately 80% contained at least one toxic ingredient; over a quarter of evaluated relaxers contained at least one formaldehyde-releasing preservative; 78% contained sodium hydroxide, calcium hydroxide, or both (EWG, February 2025; Skin Deep methodology — full-text in §9.5 backlog). The 2016-to-2025 longitudinal comparison is itself a finding: the safety gap has not meaningfully closed in nearly a decade.
Retail-environment targeting. EWG's 2025 analysis cited research showing that retail stores in neighborhoods with higher percentages of residents of color and lower socioeconomic status were more likely to stock products with higher hazard scores than stores in predominantly white neighborhoods. The exposure disparity is not only consumer preference but differential retail availability.
Health-outcome disparities. Black women have higher rates of aggressive uterine cancer subtypes (type II / non-endometrioid) (ASCO Post, October 2023). Black women are approximately twice as likely as non-Hispanic white women to die from uterine cancer (BU Chobanian & Avedisian School of Medicine press release, October 2023). The mortality gap has multiple contributors — access to care, diagnostic delays, tumor biology — but the exposure differential documented by EWG, combined with the elevated risks documented by Bertrand et al. (2023), constructs a plausible causal contribution to the outcome differential.
Environmental-justice framing. The 2017 paper by Zota and Shamasunder framing personal-care exposure disparities as "the environmental injustice of beauty" has become the scholarly anchor for the broader argument. The "beauty justice" framework (PMC 11730735, January 2025) positions relaxer-associated cancer disparities as a civil-rights and public-health issue grounded in decades of targeted marketing to Black communities. For Daubert preparation, the environmental-justice frame is not a substitute for the science; it is a frame around the science that increases the credibility cost defense incurs by attacking the science.
The April 2026 Daubert briefing in MDL 3060 is structured as follows: defendants get up to 100 pages to challenge plaintiffs' ten experts; plaintiffs respond with one 100-page brief or ten separate 10-page responses; defendants reply with 50 pages (Lawsuit Information Center, April 2026 — secondary; verify against the operative case-management order). Six defense lines are anticipated based on visible filings.
Defense will argue the Sister Study cohort consists of women each of whom had a sister with breast cancer, introducing selection bias. The plaintiff response: the Chang 2022 finding for uterine cancer is not biologically conditional on breast-cancer family history, and the dose-response gradient holds within the cohort regardless of how it was recruited. The Sister Study is also among the largest cancer-specific prospective cohorts in U.S. epidemiology — its analytical power derives precisely from its high-risk population. Self-reported product use is prospectively recorded (at enrollment, before the cancer endpoint), eliminating the differential recall that observational case-control designs are vulnerable to.
Defense will argue products contain dozens of chemicals and that plaintiffs cannot identify which specific chemical caused which specific cancer. The plaintiff response is McDonald 2021/2022 — the products as commercially formulated are hormonally active at the in-vitro receptor level. The mixture effect is not a confounding artifact; it is the exposure. Bradford Hill does not require single-chemical isolation. Plaintiffs need only show that the exposure (the relaxer product, as used) is causally associated with the outcome (hormone-sensitive cancer).
Defense will argue that obesity, physical activity, hormonal contraceptive use, family history, and socioeconomic factors may explain the observed associations. The plaintiff response: Chang et al. (2022) adjusted for age, race, BMI, smoking, parity, age at menarche, hormonal contraceptive use, and other recognized confounders. The dose-response gradient across product-use categories is not plausibly explained by residual confounding given the magnitude of the effect at frequent use. The cohort design controls for time-invariant confounding (genetic background, family history) by within-subject longitudinal observation.
Defense will argue products complied with all applicable FDA regulations at the time of sale and that no federal ban was in effect — the FDA's October 2023 proposed rule was never finalized. The plaintiff response operates on three tracks. First, the 2023 proposed rule is itself an admission that the agency considered the underlying science sufficient to justify a ban. Second, EU regulators have restricted formaldehyde in cosmetics since 2009 and tightened restrictions in July 2024; Washington State's HB 1047 (2023) bans formaldehyde-releasing chemicals in cosmetics beginning 2026 — the international and state-level record contradicts the framing of regulatory compliance as evidence of safety. Third, regulatory compliance is not a defense to a state-law failure-to-warn claim where the federal regulation does not preempt the state-law duty; the FDA's proposed rule cuts directly against any preemption argument.
L'Oréal and other defendants have requested the court divide discovery to focus exclusively on general causation first (Lawsuit Information Center, 2026 — verify against the operative case-management order). Whether bifurcation is granted is a procedural decision, but the substantive consequence is meaningful: a Daubert ruling on general causation that excludes plaintiff experts effectively ends the MDL for most plaintiffs. The April 2026 motions are therefore the pivotal moment.
The plaintiff response is structurally Bradford Hill, with the criteria substantially satisfied:
The Bradford Hill architecture — observational cohort design, mechanistic plausibility, dose-response gradient, and analogy to known endocrine carcinogens — has been accepted in multiple post-Daubert mass-tort rulings on hormonally mediated cancer endpoints (cite operative MDL Daubert orders applicable to the briefing here). No RCT is required.
Hair relaxers and cosmetics containing formaldehyde have historically been subject to minimal federal pre-market oversight. The FDA does not require pre-market safety testing for cosmetic ingredients, and formaldehyde has not been explicitly banned in cosmetic products despite IARC Group 1 classification and OSHA documentation of measured airborne concentrations multiples of the STEL during salon use. The pre-2023 regulatory architecture is itself a litigation fact: in the framework that prevailed during the plaintiff-cohort exposure period, manufacturers had no federal obligation to demonstrate safety before market entry.
In October 2023, the FDA announced a proposed rule to ban formaldehyde and formaldehyde-releasing chemicals (including methylene glycol) as ingredients in hair-smoothing or hair-straightening products. The proposed rule appears in the Unified Agenda under RIN 0910-AI83 (https://www.reginfo.gov/public/do/eAgendaViewRule?pubId=202304&RIN=0910-AI83).
The FDA has missed multiple self-imposed deadlines for finalizing the proposed ban (NPR May 2024; CNN January 2026; US News January 2026):
| Deadline | Status |
|---|---|
| April 2024 | Missed |
| November 2024 | Missed |
| March 2025 | Missed |
| July 2025 | Missed |
| December 31, 2025 | Missed |
The agency states the proposed rule "continues to remain a priority" but has offered no binding timeline (FDA statement via CNN, January 2026). On February 11, 2025, the United States notified the WTO of a proposal to amend regulations restricting formaldehyde in cosmetics, with a proposed effective date of January 1, 2027 (WTO notification — primary text on re-verification backlog).
The FDA's repeated failure to act strengthens — not weakens — the plaintiff narrative. The agency's 2023 acknowledgment is an admission, by the regulator with primary jurisdiction, that the underlying science supports the conclusion that the chemicals are unreasonably dangerous. The agency's failure to finalize the rule is consistent with regulatory capture, agency under-resourcing, or political pressure — explanations for the gap, not refutations of the science. A Daubert argument that the underlying science is unreliable runs against the contradictory fact that the FDA, applying its own scientific standards, concluded the science was reliable enough to support a federal ban.
EU Cosmetics Regulation (EC) No 1223/2009, Annex V, has restricted formaldehyde to 0.2% in cosmetic products and 0.1% in oral hygiene products since 2009. In July 2024, the European Commission amended Annex V to introduce stricter labeling requirements for formaldehyde-releasing substances, lowering the warning threshold for finished products from 0.05% to 0.001% (Personal Care Insights, 2024). Regulation (EU) 2025/877 (May 2025) added newly classified CMR substances to Annex II (prohibited ingredients), effective September 1, 2025.
Washington State HB 1047, signed by Governor Inslee in 2023, bans phthalates, PFAS, formaldehyde, and formaldehyde-releasing agents in cosmetics — the strongest state-level cosmetics regulation in the United States. Bans on most chemicals took effect in 2025; formaldehyde-releasers are subject to a phased ban beginning 2026. Washington became the first state to ban all formaldehyde-releasers in cosmetics. California's DTSC included hair-straightening products containing formaldehyde in its 2024–2026 Priority Product Work Plan but determined that pending federal and state bans made a separate listing redundant; DTSC is now developing a Priority Product profile for sodium hydroxide in hair-straightening products (DTSC Decision Document, May 2024).
The U.S./EU/Washington contrast is structural: multiple independent regulators applying their own scientific standards have concluded the formaldehyde-in-hair-products hazard is real and warrants regulation. This is independent corroboration of the plaintiff scientific case.
| Item | Detail |
|---|---|
| MDL number | 3060 |
| Full title | In re: Hair Relaxer Marketing, Sales Practices, and Products Liability Litigation |
| Court | U.S. District Court, Northern District of Illinois (Chicago) |
| Judge | Hon. Mary M. Rowland |
| MDL formation | February 6, 2023 (JPML Transfer Order, MDL 3060) |
| Approximate pending cases | 11,195 (February 2, 2026, MDL Update) |
| Ranking | Fifth-largest active MDL in the federal system |
(Verify all case-count and ranking figures against the Northern District of Illinois MDL portal and JPML pending-MDL-dockets report before relying on them in motion practice.)
Named defendants and representative product brands include L'Oréal USA (Dark & Lovely, Optimum, Mizani); Revlon (Crème of Nature); Strength of Nature (Just for Me, Motions, African Pride, TCB, Dr. Miracle's); Dabur / Namaste Laboratories (ORS Olive Oil); PDC Brands (Cantu); McBride Research Laboratories (Design Essentials); Avlon Industries (Affirm). (Source: master complaint via classaction.org; relaxercancer.com, March 2026 — secondary; confirm against the operative consolidated complaint.)
| Date | Event |
|---|---|
| January 8, 2026 | Science Day hearing |
| February 23, 2026 | Bellwether case-selection process begins |
| March 2, 2026 | General-causation expert discovery closes |
| March 18, 2026 | Fact discovery closes on 32-case pool |
| April 1, 2026 | Rule 702 / Daubert motions on general causation due |
| April 2026 | Bellwether picks expected |
| June 10, 2026 | Additional bellwether fact discovery closes |
| November 16, 2026 | Daubert and summary-judgment motions due |
| Mid-2027 | First bellwether trials expected |
(Sources: millerandzois.com, May 2026; lawsuit-information-center.com, April 2026; aboutlawsuits.com, 2026 — secondary; verify against the operative case-management order.)
Judge Rowland has expanded the bellwether discovery pool beyond the initial 16-case agreement. The court is targeting 40 cases for discovery, aiming for up to 12 to proceed to trial (millerandzois.com, May 2026; confirm against operative case-management order docket entry). The expanded pool is plaintiff-favorable: a wider sample increases the probability that the trial-bellwether pool includes cases with strong individual specific-causation profiles, reducing defense leverage to cherry-pick the weakest cases.
The April 2026 Daubert motions are the procedural inflection. If the court finds plaintiffs' expert testimony on general causation admissible, the path to mid-2027 bellwether trials remains open and the litigation moves into specific-causation, damages, and settlement-pressure phases. A ruling excluding key expert testimony — particularly testimony tied to Chang 2022, McDonald 2021/2022, or White 2021 — would substantially narrow the litigation and could effectively foreclose the MDL for most plaintiffs. The April 2026 hearings concentrate the litigation's strategic risk in a single procedural moment.
The plaintiff case on general causation is structurally strong. The remaining gaps are operational.
The dose-response gradient is the most decisive single Bradford Hill criterion. Specific-causation analysis depends on placing each plaintiff at a defined point on the duration / frequency curve. Plaintiff intake records vary in completeness — relaxer use is rarely documented in medical records, salon receipts are not retained for decades, and home-use frequency is typically reconstructed from patient memory. Adopt a uniform exposure-documentation protocol across firms: structured intake interviews capturing age at first use, application frequency, product brand, salon-versus-home split, and number of self-reported chemical-burn events. The chemical-burn count is particularly load-bearing given Wise 2012. Document gaps explicitly rather than inferring exposure.
The strongest specific-causation cases will have prospective documentation of long-term use, a clear cancer endpoint matching one of the studied associations, demographic profile matching the cohort populations, and absence of strong competing risk factors. For atypical cases — short-duration use, unusual cancer subtypes, or strong genetic/family-history confounders — the theory must be developed more carefully or the case re-tiered. For each plaintiff, obtain pathology records and where feasible histologic subtyping; estrogen-receptor and progesterone-receptor status of the tumor should be in the file.
Specific-causation tiering should weight postmenopausal plaintiffs differently from premenopausal plaintiffs given the Bertrand 2023 stratification (premenopausal results null; postmenopausal HRs 1.60–1.71). The general-causation Daubert posture is unaffected — Chang's full-cohort signal stands — but premenopausal-only specific-causation cases on uterine cancer are weaker on the BWHS data and should rely on Sister Study coverage or alternative endpoint pleading (fibroids per Wise 2012; ovarian per White 2021). Case-acceptance posture and damages valuation should reflect this gradient.
Develop a uniform plaintiff brief on the Daubert "fit" question for mixture exposures, anchored on McDonald 2021/2022 (products as commercially formulated are hormonally active in vitro at the receptor level) and the Helm 2018 chemical inventory. The conceptual move is that the exposure is the product, not any single chemical, and the epidemiology measures the product association. Anticipate the defense argument that mixture-effect epidemiology is inherently confounded and answer with the specificity findings (Chang's product-class specificity for straighteners not dyes; White's histologic specificity for non-serous not serous ovarian cancer) — both inconsistent with confounding-driven artifacts.
Plaintiffs whose relaxer exposure preceded the litigation by many years face statute-of-limitations exposure in jurisdictions without robust discovery rules. The available anchor dates are the Chang 2022 publication (October 2022, with NIH press release the same month); the Bertrand 2023 publication; the FDA's October 2023 proposed-ban announcement; and the various bellwether-trial dates. The strongest single anchor for older plaintiffs is the FDA October 2023 announcement — a date at which a reasonable plaintiff could be charged with public-notice knowledge. Develop a uniform SOL brief and state-by-state matrix mapping discovery-rule recognition, public-notice anchors, and any state toleration of latent-injury or continuing-tort theories. The operative anchor date should be identified at intake, not litigated reactively.
Several elements of the plaintiff narrative rest on secondary sources or materials that should be primary-source-confirmed before the April 2026 Daubert hearings:
Build a re-verification schedule keyed to the April 2026 Daubert hearing. Each load-bearing claim resting on a secondary source must be re-verified or removed from the load-bearing position before that hearing. A single mis-cited secondary source in expert testimony can ground a Rule 702 challenge that bleeds into the broader expert opinion.
Defense expert reports often originate with consultancies that have ongoing financial relationships with the cosmetics industry. Plaintiff teams should obtain Rule 26 disclosures, identify funding relationships, and prepare cross-examination on consulting income, prior testimony, and any past advocacy in regulatory-comment proceedings (FDA, EU, Washington State, California DTSC).
Damages models should be patient-specific, not population-aggregate. SEER-derived survival aggregates are vulnerable in cases with favorable individual prognosis. Replace aggregate models with stage-specific, treatment-specific, and demographic-specific models. Account for surgical complications (hysterectomy with bilateral salpingo-oophorectomy; oophorectomy in ovarian cases), fertility loss in premenopausal plaintiffs, recurrence-monitoring lifetime cost, and employment-reentry difficulty. The differential mortality data (Black women's approximately 2× uterine-cancer mortality) is relevant to demographic-specific damages calibration.
Six concrete priorities:
This memorandum is prepared as background research and does not constitute legal advice. Citations to primary peer-reviewed sources have been verified to publicly accessible URLs as of the memo date. Secondary-source claims and snapshot values (case counts, regulatory deadlines, bellwether-pool size) are flagged inline and detailed in §9.5; recipients should clear the §9.5 backlog before relying on those elements in motion practice or expert testimony, including at deposition or at the April 2026 Daubert hearings. Recipients should independently verify case names, docket numbers, settlement projections, and current MDL status before relying on this material in court.
We produce custom litigation research memos — cross-domain synthesis connecting medical science, regulatory filings, expert witness analysis, and case law for specific MDLs. Each memo is adversarial-reviewed before delivery.
$1,500 – $7,500 per memo depending on scope and docket complexity.
Contact: alex@vibeagentmaking.com